Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Diseases
81%
Pancreas Cancer
71%
Overall Survival
64%
Metastatic Carcinoma
57%
Neoplasm
45%
Neoadjuvant Therapy
43%
Cancer of Unknown Primary Origin
40%
Abdominal Cancer
38%
Malignant Neoplasm
35%
Systemic Therapy
35%
Arm
30%
Primary Tumor
28%
Hazard Ratio
25%
Metastatic Colorectal Cancer
23%
Surgery
23%
Treatment Response
21%
Phase II Trials
21%
Stomach Adenocarcinoma
20%
Neoadjuvant Chemotherapy
20%
Pembrolizumab
20%
Colorectal Carcinoma
18%
Adjuvant Therapy
17%
Radiation Therapy
17%
Oxaliplatin
16%
Fluorouracil
16%
Cytotoxic T-Cell
15%
Esophagectomy
14%
T Cell
14%
Progression Free Survival
13%
Combination Therapy
13%
Liquid Biopsy
13%
Cell Therapy
13%
Gemcitabine
13%
Lymph Node
11%
Anemia
11%
Monoclonal Antibody
11%
First-Line Chemotherapy
11%
Proportional Hazards Model
10%
Perineural Invasion
10%
CA 19-9 Antigen
10%
Solid Malignant Neoplasm
10%
Bevacizumab
10%
Microsatellite Instability
10%
Combined Therapy
10%
Growth Factor Receptor
10%
Chronic Kidney Disease
10%
Intraductal Papillary Mucinous Tumor
10%
Clinical Feature
10%
Exosome
10%
Keyphrases
Pancreatic Ductal Adenocarcinoma
79%
Overall Survival
40%
Pancreatic Cancer
35%
Neoadjuvant Therapy
33%
Chemotherapy
32%
Metastatic Disease
31%
Resectable Pancreatic Cancer
30%
Prognostic Value
30%
Cancer of Unknown Primary
30%
Metastatic Pancreatic Ductal Adenocarcinoma
29%
Systemic Therapy
24%
KRAS mutation
24%
Carbohydrate Antigen 19-9 (CA19-9)
24%
Nodal Response
22%
Gastric Cancer
22%
Hazard Ratio
21%
Phase II Study
21%
Metastatic Pancreatic Cancer
21%
Treatment Response
20%
Gastric Adenocarcinoma
20%
Veliparib
20%
Pembrolizumab
20%
Anti-metastasis
20%
Oligometastatic
20%
Randomized Phase II Trial
20%
Median Overall Survival
19%
Neoadjuvant Chemotherapy
17%
ABT-888
17%
Cancer Cells
17%
In Cancer
17%
Pancreatic Adenocarcinoma
17%
Tumor
16%
Clinical Outcomes
15%
Risk of Death
15%
Confidence Interval
14%
Primary Tumor
14%
High-risk Features
14%
Immune Checkpoint Inhibitors
14%
Liquid Biopsy
13%
Single Center
13%
First-line Chemotherapy
13%
Solid Tumors
13%
Pathological Response
13%
Post-resection
13%
Combination Therapy
12%
Progression-free Survival
12%
Single Institution
12%
Immunoconjugate
12%
Monoclonal Antibody
12%
Objective Response Rate
12%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
83%
Neoplasm
62%
Diseases
52%
Malignant Neoplasm
49%
Overall Survival
44%
Chemotherapy
43%
Pancreas Cancer
41%
Progression Free Survival
28%
Combination Therapy
26%
Primary Tumor
24%
Metastatic Colorectal Cancer
23%
Phase II Trials
22%
Monoclonal Antibody
21%
Maximum Tolerated Dose
17%
Clinical Trial
17%
Colorectal Carcinoma
16%
CD8 Antigen
15%
Solid Malignant Neoplasm
15%
Metastasis
15%
Anemia
15%
Pharmacokinetic
13%
Immunotherapy
13%
Adverse Event
12%
Immune Checkpoint Inhibitor
11%
Bevacizumab
10%
Chronic Kidney Failure
10%
Bortezomib
10%
Artesunate
10%
Sorafenib
10%
Growth Factor Receptor
10%
Cancer of Unknown Primary Site
10%
Antibody Conjugate
10%
Abdominal Cancer
10%
Randomized Clinical Trial
10%
Hormone Cancer Therapy
10%
Folinic Acid
10%
Liver Cell Carcinoma
10%
Pembrolizumab
10%
First-Line Chemotherapy
10%
Oncolytic Virus
10%
Paclitaxel
10%
Proteasome Inhibitor
10%
Lapatinib
10%
Cardiovascular Risk
10%
Endothelial Cell Growth Factor
10%
Ixabepilone
10%
Temozolomide
10%
Gemcitabine
10%
Anticarcinogen
10%
Phosphotransferase Inhibitor
10%